ProCE Banner Activity

Beware of the Troll: Preventing CMV After Solid Organ Transplantation

Clinical Thought

Here’s what I consider when selecting between universal prophylaxis and preemptive therapy to prevent CMV disease in high-risk solid transplant recipients.

 

Released: August 30, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA

Merck & Co., Inc., Rahway, NJ, USA

Disclosure

Primary Author

Hannah Imlay, MD, MS

Assistant Professor 
Internal Medicine/Infectious Diseases 
University of Utah 
Salt Lake City, Utah 

Hannah Imlay, MD, MS, has no relevant financial relationships to disclose.